Stocks soared Wednesday as investors digested strong earnings reports from several large financial services companies and highly anticipated inflation numbers that came in softer than expected.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...